NovaBridge Biosciences Cash and Cash Equivalents
NovaBridge Biosciences (NBP) had Cash and Cash Equivalents of $210.63 million as of 2025-12-31, per its 20-F filed 2026-04-07.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-04-07
- 2023-12-31: Cash and Cash Equivalents, at Carrying Value 2.14B CNY.
- 2022-12-31: Cash and Cash Equivalents, at Carrying Value 3.21B CNY.
- 2022-06-30: Cash and Cash Equivalents, at Carrying Value 3.71B CNY.
- 2021-12-31: Cash and Cash Equivalents, at Carrying Value 3.52B CNY.
CNY
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2023-12-31 | 2.14B CNY 20-F · filed 2024-04-30 |
| 2022-12-31 | 3.21B CNY 20-F · filed 2024-04-30 |
| 2022-06-30 | 3.71B CNY 6-K · filed 2022-11-10 |
| 2021-12-31 | 3.52B CNY 20-F · filed 2023-05-01 |
| 2020-12-31 | 4.76B CNY 20-F · filed 2022-04-29 |
| 2020-09-30 | 2.96B CNY 6-K · filed 2021-02-05 |
| 2019-12-31 | 1.14B CNY 20-F · filed 2021-04-28 |
| 2018-12-31 | 1.59B CNY 20-F · filed 2020-04-29 |
USD
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2025-12-31 | $210.63M 20-F · filed 2026-04-07 | |
| 2025-09-30 | $228.06M 6-K · filed 2025-12-18 | |
| 2025-06-30 | $165.40M 6-K · filed 2025-10-06 | |
| 2024-12-31 | $68.26M 20-F · filed 2026-04-07 | |
| 2023-12-31 | $291.51M 20-F · filed 2026-04-07 | $301.62M 20-F · filed 2024-04-30 |
| 2022-12-31 | $342.92M 20-F · filed 2025-04-03 | $465.99M 20-F · filed 2023-05-01 |
| 2022-06-30 | $554.02M 6-K · filed 2022-11-10 | |
| 2021-12-31 | $552.93M 20-F · filed 2022-04-29 | |
| 2020-12-31 | $729.32M 20-F · filed 2021-04-28 | |
| 2020-09-30 | $435.96M 6-K · filed 2021-02-05 | |
| 2019-12-31 | $163.39M 20-F · filed 2020-04-29 |